ALXO vs AMGN vs EXEL vs CRL

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Exelixis, Inc. (EXEL) offers the better valuation at 16. 6x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate ALX Oncology Holdings Inc. (ALXO) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Exelixis, Inc.

(EXEL) is the cheapest at 16. 6x versus Amgen Inc. at 23. 1x. On forward P/E, Exelixis, Inc. is actually cheaper at 14. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Exelixis, Inc. wins at 0. 27x versus Amgen Inc. 's 5. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Exelixis, Inc.

(EXEL) delivered a total return of +84. 0%, compared to -97. 1% for ALX Oncology Holdings Inc. (ALXO). Over 10 years, the gap is even starker: EXEL returned +833. 5% versus ALXO's -93. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 60β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 153% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Exelixis, Inc. (EXEL) carries a lower debt/equity ratio of 8% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Amgen Inc. grew EPS 88. 2% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, EXEL leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exelixis, Inc.

(EXEL) is the more profitable company, earning 33. 7% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37. 6% versus 0. 0% for ALXO. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Exelixis, Inc. (EXEL) is the more undervalued stock at a PEG of 0. 27x versus Amgen Inc. 's 5. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Exelixis, Inc. (EXEL) trades at 14. 0x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 2. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALXO: 113. 9% to $4. 00.

In this comparison, AMGN (2.

9% yield) pays a dividend. ALXO, EXEL, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 2. 9% yield, +156. 4% 10Y return). Both have compounded well over 10 years (AMGN: +156. 4%, ALXO: -93. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ALXO is a small-cap quality compounder stock; AMGN is a mid-cap quality compounder stock; EXEL is a mid-cap deep-value stock; CRL is a small-cap quality compounder stock. AMGN pays a dividend while ALXO, EXEL, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.